Preferred Label : GLP-1 Mimetics;

NCIt synonyms : GLP-1 Analogue;

NCIt related terms : GLP-1 receptor agonist;

NCIt definition : Any of the analogues of the endogenous gastrointestinal hormone glucagon-like peptide-1 (GLP-1) with antihyperglycemic activity. GLP-1 mimetics mimic the activity of GLP-1 and thereby stimulate glucose-dependent secretion of insulin from pancreatic beta cells, suppress glucagon secretion from alpha cells, increase insulin sensitivity and inhibit gastric emptying thereby slowing absorption of nutrients and creating a satiating effect. Altogether, this lowers blood glucose levels. GLP-1 is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).;

Alternative definition : ACC/AHA: Select medications in this class have been shown to improve ASCVD outcomes, drive weight loss, and lower glucose.;

Details


Main resources

You can consult :


https://ansm.sante.fr/actualites/retour-dinformation-sur-le-prac-de-novembre-2023-23-26-octobre
2023
false
false
false
France
French
drug information
risk assessment
thyroid neoplasms
glucagon-like peptide 1
hypoglycemic agents
GLP-1 Mimetics
Glucagon-like peptide-1 (GLP-1) analogues

---
https://ansm.sante.fr/actualites/creation-dun-comite-scientifique-temporaire-pour-analyser-lusage-des-analogues-du-glp-1
2023
false
false
false
France
French
drug utilization
drug utilization review
GLP-1 Mimetics
Glucagon-like peptide-1 (GLP-1) analogues
glucagon-like peptide 1
Off-Label use
drug information

---
https://www.sfdiabete.org/sites/www.sfdiabete.org/files/files/ressources/reco_sfd_surveillance_glycemique_mars2017.pdf
2018
false
false
false
France
French
blood glucose self-monitoring
glucagon-like peptide 1
practice guideline
patient education as topic
Glucagon-like peptide-1 (GLP-1) analogues
injections, subcutaneous
GLP-1 Mimetics
Capillary blood glucose measurement (procedure)
Capillary specimen collection (procedure)
acetone
acetone
diabetes mellitus
continuity of patient care
ketosis
ketosis
diabetes mellitus
blood glucose
quality control
insulin
Insulin lipohypertrophy (disorder)
Subcutaneous injection of insulin (procedure)
Subcutaneous injection of insulin (procedure)
Insulin administration assessment (procedure)
questionnaires
Initiation of first time insulin therapy (regime/therapy)

---
https://www.revmed.ch/RMS/2017/RMS-N-565/Association-des-analogues-du-GLP-1-et-des-inhibiteurs-du-SGLT2-de-nouvelles-perspectives
2018
false
false
false
Switzerland
French
journal article
administration, oral
hypoglycemic agents
diabetes mellitus, type 2
switzerland
treatment outcome
body weight
cardiovascular diseases
drug therapy, combination
GLP-1 Mimetics
glucagon-like peptide 1
Glucagon-like peptide-1 (GLP-1) analogues
SGLT2 Inhibitor
Sodium-Glucose transporter 2
dulaglutide
Liraglutide
empagliflozin
dapagliflozin
Canagliflozin
blood glucose
arterial pressure
genetic pleiotropy
Sodium-glucose co-transporter 2 (SGLT2) inhibitors
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
peptides
venoms
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
benzhydryl compounds
glucosides
Exenatide

---
https://smf.swisshealthweb.ch/fr/article/doi/fms.2016.02684/
2016
false
false
false
Switzerland
French
journal article
diabetes mellitus, type 2
dipeptidyl-peptidase iv inhibitors
practice guidelines as topic
glucagon-like peptide 1
GLP-1 Mimetics
GLP-1 Mimetics
dipeptidyl-peptidase iv inhibitors
cardiovascular diseases
obesity
Sodium-Glucose transporter 2
SGLT2 Inhibitor
SGLT2 Inhibitor
insulins
risk factors
weight loss
hypoglycemia
insulins
hypoglycemic agents
Sodium-Glucose Transporter 2 Inhibitors

---
http://www.riziv.fgov.be/SiteCollectionDocuments/consensus_litterature_resume_20161117.pdf
2016
false
false
false
Belgium
French
GLP-1 Mimetics
diabetes mellitus, type 2
review of literature
consensus
GLP-1 Mimetics
treatment outcome
albiglutide
albiglutide
Glucagon-like peptide-1 (GLP-1) analogues
drug therapy, combination
metformin
hypoglycemic agents
hypoglycemic agents
glimepiride
dulaglutide
dulaglutide
Liraglutide
Liraglutide
Sitagliptin Phosphate
sulfonylurea compounds
comparative effectiveness research
arterial pressure
insulin
thyroid neoplasms
pancreatitis
Injection Site Reaction
cardiovascular diseases
practice guidelines as topic
Evidence-Based medicine
rGLP-1 protein
rGLP-1 protein
glucagon-like peptide 1
glucagon-like peptide 1
glucagon-like peptide 1
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
glucagon-like peptides
immunoglobulin fc fragments
recombinant fusion proteins
glucagon-like peptides
peptides
venoms
peptides
venoms
thiazolidinediones
Pioglitazone
Exenatide
Exenatide

---
http://www.revmed.ch/RMS/2015/RMS-N-477/Analogues-du-GLP-1-versus-inhibiteurs-du-SGLT-2-pour-les-diabetiques-de-type-2-obeses
2015
false
false
false
Switzerland
French
diabetes mellitus, type 2
obesity
comparative effectiveness research
treatment outcome
incretins
hypoglycemic agents
Liraglutide
glucagon-like peptide 1
Canagliflozin
Sodium-Glucose transporter 2
SGLT2 Inhibitor
dapagliflozin
empagliflozin
1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol
other blood glucose lowering drugs, excl. insulins
GLP-1 Mimetics
journal article
Sodium-Glucose Transporter 2 Inhibitors
dapagliflozin
dapagliflozin
glucosides
benzhydryl compounds
peptides
venoms
sorbitol
sorbitol
Exenatide

---
Nous contacter.
08/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.